There are 2949 resources available
LBA58 - ORR in patients receiving nivolumab plus radiotherapy in advanced non-small cell lung cancer: First results from the FORCE trial
Presenter: Farastuk Bozorgmehr
Session: Mini Oral - NSCLC, metastatic
Resources:
Abstract
Slides
Webcast
534MO - First in human study of ONO-4578, a PGE2-receptor EP4 antagonist, in monotherapy and combination with PD-1 checkpoint inhibitor nivolumab in patients with advanced or metastatic solid tumours
Presenter: Noboru Yamamoto
Session: Mini Oral - Developmental therapeutics
Resources:
Abstract
Slides
Webcast
535MO - BGB-A333, an anti-PD-L1 monoclonal antibody, in combination with tislelizumab in patients with urothelial carcinoma
Presenter: Juan Martin Liberal
Session: Mini Oral - Developmental therapeutics
Resources:
Abstract
Slides
Webcast
536MO - A phase I, first-in-human, safety, pharmacokinetic, and pharmacodynamic study of oral dubermatinib (TP-0903) in patients with advanced solid tumours
Presenter: John Sarantopoulos
Session: Mini Oral - Developmental therapeutics
Resources:
Abstract
Slides
Webcast
537MO - First-in-human study of JNJ-64619178, a protein arginine methyltransferase 5 (PRMT5) inhibitor, in patients with advanced cancers
Presenter: Maria Vieito Villar
Session: Mini Oral - Developmental therapeutics
Resources:
Abstract
Slides
Webcast
LBA88 - Anlotinib in locally advanced or metastatic radioiodine-refractory differentiated thyroid carcinoma: A randomized, double-blind, multicenter phase II trial
Presenter: Yihebali Chi
Session: Mini Oral - NETs and endocrine tumours
Resources:
Abstract
Slides
Webcast
LBA89 - A randomized multicentered phase III study to evaluate apatinib in subjects with locally advanced or metastatic radioactive iodine-refractory differentiated thyroid cancer
Presenter: Yansong Lin
Session: Mini Oral - NETs and endocrine tumours
Resources:
Abstract
Slides
Webcast
1914MO - Randomized phase II study of radiation therapy and paclitaxel with pazopanib or placebo: NRG-RTOG 0912
Presenter: Eric Sherman
Session: Mini Oral - NETs and endocrine tumours
Resources:
Abstract
Slides
Webcast
1158MO - Metabolomic profile of advanced neuroendocrine cancer patients
Presenter: Beatriz Soldevilla
Session: Mini Oral - NETs and endocrine tumours
Resources:
Abstract
Slides
Webcast
1422MO - Trastuzumab deruxtecan (T-DXd; DS-8201) in patients with HER2-low, advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma: Results of the exploratory cohorts in the phase II, multicenter, open-label DESTINY-Gastric01 study
Presenter: Kensei Yamaguchi
Session: Mini Oral - Gastrointestinal tumours, non-colorectal
Resources:
Abstract
Slides
Webcast